Cancer is a deadly disease caused by uncontrolled cell growth. It is the world’s leading cause of death, followed by heart disease and stroke. According to Cancer Research UK, almost half of all people will be diagnosed with cancer during their lifetimes, and half of those will die from the disease. The 2012 World Health Organisation Cancer Report predicted “an imminent human disaster”, with the approximately 15 million new cases of cancer occurring worldwide annually expected to almost double within the next 20 years.
Current cancer drug therapy is largely limited to delaying the disease’s lethality. The cancer drug market has been, and for the foreseeable future will continue to be, dominated by conventional chemotherapy; however, targeted therapy and immunotherapy are rapidly gaining traction.
Some industry analysts are calling next-generation immunotherapy the “beginning of the end” for cancer, reflecting the quantum leap in patient response rates being demonstrated for immuno-oncology therapies in late stage clinical development. Cancure’s pipeline is at the forefront of targeted therapy and immunotherapy for cancer.